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1. Introduction  
Cancer incidence in humans has gradually increased over the last century. Surgical, radio, 
chemotherapeutic and biological treatments have experienced important advances, with 
concomitant reduction in the morbidity associated with the radical surgical practices of the 
past. The term “oral cancer” includes a diverse group of tumors arising from the oral cavity 
(Khalili, 2008). Usually included are cancers of the lip, tongue, pharynx, and oral cavity. The 
World Health Organization (WHO) reported oral cancer as having one of the highest 
mortality ratios amongst all malignancies (Parkin et al., 2000). Although oral cancer is rare 
and attracts little attention, it is more common than Hodgkin’s disease tumours of brain, 
liver, bone, thyroid gland, stomach, ovaries, or cancer of the cervix. It ranks 12th among all 
cancers (Jemal et al., 2002). The vast majority of malignant neoplasms in the mouth are 
squamous cell carcinomas. Oral cancer incidence and mortality rates vary widely across the 
world. Mortality rate is an important tool that provides implicit information about 
incidence, diagnosis stage, solving capacity of health services, available technology and 
health programs to be applied. Although globally oral cancer represents an incidence of 3% 
(males) and 2% (females) of all malignant neoplasm, it has one of the lowest survival rates 
— 50 percent, within a five-year period (Greenlee et al., 2001). 
It is important to diagnose oral cancer in its early stages, since the management of small and 
localized tumors involves less morbidity and mortality than more advanced-stage disease, 
where treatment must be more aggressive. Indeed, the stage in which the disease is 
diagnosed is directly correlated to long-term survival. (Onizawa et al., 2003). It is generally 
accepted that when diagnosed in its early stages, a favorable prognosis is expected, with a 
survival rate exceeding 90% at the 5-year follow-up. However, reviewing the literature 
exposes a less optimistic picture, because lymph node metastases seem to occur in 5% to 
20% of cases (Regev et al., 1992, Khalili, 2008). However, in practice many malignancies are 
diagnosed and treated in advanced stages and/or once the patients have already 
experienced symptoms causing them to seek medical help. This explains the great interest in 
improving multidisciplinary therapies, and particularly in establishing more reliable 
techniques for diagnosing and prognosis of the illness (Miller & Kearney N, 2001). 
The membrane, which defines the extent of the cell, is not only a physical boundary but also 
has many specific functions, among which is the capacity to react with other cells and the 
intracellular matrix (Ebnet & Vestweber, 1999, Hascall, 2000). Carbohydrates are structures 
found on the cell surface bound to either lipid or protein embedded in the membrane. 
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Changes in the carbohydrate structure of these cell-surface glycolipids and glycoproteins 
have been demonstrated during development, during cell maturation in adult tissue, and in 
relationship to malignant development. 
Biochemical and molecular genetic studies have contributed to our molecular knowledge of 
blood group-associated molecules in the past few years (Dabelsteen, 1996, Fenderson et al., 
Fukuda, 2002, 1986, Hakomori, 1999, 2002, 2003, Le Pendu et al., 2001). Among the 30 blood 
group systems presently identified, almost all have a molecular basis and present 
investigations are oriented towards the analysis of genetic polymorphisms, tissue-specific 
expression and structure-function relationships. Antigens defined by carbohydrate 
structures, among which ABO, Hh, Lewis and Secretor are the main representative species, 
are indirect gene products (Hakomori et al., 1967). They are synthesized by Golgi-resident 
glycosyltransferases, which are the direct products of the blood group genes. Cell-surface 
carbohydrates are built up in a stepwise fashion when monosaccharides are tranferred from 
their sugar nucleotide derivatives to appropriate acceptors. Each particular type of transfer 
is catalyzed by a unique specific glycosyltransferase. In tumors, changes in glycosylation are 
found in both glycolipids and glycoproteins (Hakomori, 1999; Le Pendu et al., 2001). Most 
studies have dealt with alteration of carbohydrates at the cell surface. However, several 
recent studies have shown that altered glycosylation plays a major role in most aspects of 
the malignant phenotype, including signal transduction and apoptosis. These studies have 
recently been reviewed (Hakomori, 2002; Hakomori & Handa, 2002, Dabelsteen &  Gao, 
2004). Historical studies associating the Lewis system antigens and/or ABH system 
secretory antigens with disease are varied and generally inconclusive.  Critical analysis of 
these studies reveals that in many instances the serology is inadequate, mainly as a result of 
unappreciated difficulties in accurately phenotyping diseased individuals (Svensson, 2000). 
Before a detailed account of the immunochemistry and genetics is presented, a brief 
summary will be given in order to orient the general reader. The A and B antigens were 
originally detected on erythrocytes by means of isoagglutinins in the serum of persons 
lacking these determinants. These antigens are synthesized from a common intermediate, H 
substance, by addition of a single sugar to the non reducing end of H oligosaccharide 
chains, and the immunologic reactivity of the H antigen is markedly decreased by the 
additional sugar. Group O erythrocytes and the saliva of group O secretors contain the H 
antigen. Even though the O antigen does not exist, the designation group O erythrocytes 
have been retained for historical reasons. The blood group H antigen is an oligosaccharide 
molecule whose expression is normally restricted to the surfaces of human erythrocytes and 
a variety of epithelial cells, including those that line the gastrointestinal, urinary, and 
respiratory tracts (Larsen et al. 1990). The H antigen is a fucosylated structure of the form 
Fucal-2Galf3-, whose expression is determined by GDP-L-fucose:P-D-galactoside 2-a-L-
fucosyltransferases [a(1,2)Frs; EC 2.4.1.69]. These enzymes catalyze a transglycosylation 
reaction between their sugar nucleotide substrate GDP-L-fucose and oligosaccharide 
acceptor substrates with terminal type I (Gal81-3GlcNAc-) or type II (Gal, 81-4GlcNAc-) 
moieties.  The secretor status is defined by the presence of H type 1 antigen in body 
secretions such as milk and saliva. H type 1 antigen belongs to both the Lewis and the 
ABO(H) histo-blood-group systems and is expressed in erythrocyte  membranes and in 
several epithelial tissues, namely the gastricmucosa, the upper respiratory tract and the 
lower genito-urinary tract. Approximately 75 per cent of white persons secrete glycoproteins 
containing the same A, B or H antigens present on their erythrocytes (Moreno et al., 2009). 
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The Lewis antigens, Lea and Leb, are also found on erythrocytes and glycoproteins. These 
antigens appear on the same glycoproteins as the ABH determinants, but their synthesis is 
regulated by the independent gene Le. The operation of these independent genes on a 
common substrate results in a complex phenotypic interaction (Henry et al., 1995). 
It is well established that the large array of functions that a tumour cell has to fulfill to settle 
as a metastasis in a distant organ requires cooperative activities between the tumour and the 
surrounding tissue and that several classes of molecules are involved, such as cell-cell and 
cell-matrix adhesion molecules and matrix degrading enzymes, to name only a few. Cell 
adhesion molecules are found on the surfaces of all cells, where they bind to extracellular 
matrix molecules or to receptors on other cells. Cell adhesion is critical in the dynamic 
processes necessary for tissue morphogenesis in development and the maintenance of 
complex differentiated tissues in adult organisms. Adhesion molecules have originally been 
thought to be essential for the formation of multicellular organisms and to tether cells to the 
extracellular matrix or to neighbouring cells (Marhaba & Zöller, 2004).  CDD44 is the major 
human cell surface receptor for hyaluronate and functions in a diverse range of 
physiological processes. CD44 may play a role in stimulating in vivo aggressiveness of 
tumors through hyaluronate-rich stroma (Hudson et al., 1996). Expression of CD44 has been 
described to correlate with metastasis formation in various tumors, although evidence in 
oral cavity cancers is inconclusive. 
2. ABO antigens 
Although the ABO blood group antigens were initially identified as erythrocyte substances 
with a significance mainly ascribed to serology, it soon became clear that these antigens 
were found on most epithelial cells and in secretions (Landsteiner, 1900). These ABH 
antigens are carbohydrate antigens which in epithelia are expressed in a highly regulated 
way that correlates with the pattern of epithelial differentiation and with cell maturation 
(Ravn & Dabelsteen, 2000). 
Profound changes in expression have been documented during epithelial cell migration in 
wound healing and in pathological processes such as malignant development, including 
oral carcinoma (Dabelsteen, 1996, Dabelsteen et al., 1998, Hakomori, 1996, Le Pendu et al., 
2001). Tumor progression is often associated with altered glycosylation of the cell-surface 
proteins and lipids (Hakomori, 1996). The peripheral parts of these cell-surface 
glycoconjugates often carries many of the target molecules that reside in blood are also 
present in oral fluids, albeit at lower concentrations. Oral fluids are, however, relatively easy 
and safe to collect without the need for specialized equipment and training. Thus, oral fluids 
provide convenient samples for medical diagnostics, carbohydrate structures related to the 
ABO and Lewis blood-group antigens. The expression of histo-blood-group antigens in 
normal human tissues is dependent on the type of differentiation of the epithelium. In most 
human carcinomas, including oral carcinoma, a significant event is the decreased expression 
of histo-blood-group antigens A and B (Hakomori, 1999). The mechanisms of aberrant 
expression of blood-group antigens are not clear in all cases (Hamokori & Handa 2002, Le 
Pendu et al., 2001, Gao 2004a, 2004b). A relative down-regulation of the glycosyltransferase 
that is involved in the biosynthesis of A and B antigens is seen in oral carcinomas in 
association with tumor development (Hakomori, 1999, Le Pendu et al., 2001). However, 
several recent studies have shown that altered glycosylation plays a major role in most 
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aspects of the malignant phenotype, including signal transduction and apoptosis. Studies of 
associations between various cancers and the ABO blood groups have shown elevated 
relative risks for some categories of disease (Campi et al., 2007, Khalil, 2008). 
To investigate the association of expression of ABH antigens and oral cancer, we conducted 
a study of premalignant lesions and diagnosed malignant tumors. The patients analyzed in 
this study presented to the Stomatology Department of The Odontology Faculty of the 
National University of Rosario, Argentina during two years. In total 132 subjects were 
examined, half of whom suffered from oral pre-cancerous and cancerous lesions, while the 
other half were the control group (benign lesions: mucosceles, papiloma, etc). All of them 
were subjected to clinical oral examinations. In the group of patients with oral pre-cancerous 
and cancerous lesions (experimental group), a pathohistological examination of the oral 
mucosa was performed (Biondi et al., 2008). 
All biopsies were fixed in 4% buffered formaldehyde, paraffin embedded, sectioned at 4μm, 
and stained with hematoxilyn and eosin. Sections (4 μm) from the tumor biopsies were 
placed on gelatine-coated slides. Sections were deparaffinized in xylene and brought to 
water through graded ethanol (100%). 
2.1 Specific red cell adherence test 
Specific red cell adherence test was performed on paraffin embedded sections to detect the 
intensity of isoantigens A, B and H (O) on the epithelial cell surface by a three layer 
sandwich technique, as described in (Vengelen-Tyler, V.  2002, Strauchen et al., 1980). 
Commercially available Anti A, Anti B, and Anti AB antisera from Span Diagnostic Limited 
and Ulex europaeus lectin (Anti H) were used. Slides of 4-5 micron section were 
deparaffinized and brought to water, immersed in Tris buffered saline 0.05 M (pH 7.4) for 30 
minutes, covered with isologous antisera according to patients’ blood group, and incubated 
for one hour with Anti- A, -B and -O antisera in a moist chamber at room temperature. The 
slides were then dipped in Tris buffered saline three times with occasional stirring to 
remove the unreacted antisera. A few drops of 2-5% isologous indicator RBC’s suspension 
were added to the sections and incubated for 20 minutes in group A or B and one hour for 
group O. The slides were inverted over a support in a petridish containing Tris buffered 
saline such that the undersurface of the slide just touched the solution, and kept for five 
minutes to settle unreacted RBCs down. The slides were observed under low power 
magnification and photographed immediately. 
Normal tissues containing blood group antigens, endothelium of blood vessels and RBCs 
acted as inbuilt positive controls, and adipose tissues acted as inbuilt negative controls. 
In the present study the isoantigenicity of the epithelium was graded according to degree of 
adherence of indicator RBCs as strongly positive adherence (++++) to negative adherence (-
). Intermediate levels were graded as + for 25% of adherence, ++ for 50% of adherence, and 
+++ for 75% of adherence. 
The immunoadherence reaction to tissue sections using antibodies and red blood cells 
showed a significant loss of A, B or H antigens related to the stage of tumor development 
and the histological grade of malignancy (Table 1).  
In the tissue sections studied, the endothelium of blood vessels was reactive with the 
erythrocytes (positive control), and adipose tissues did not react with the red blood cells 
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(negative controls). Loss of A, B, and H antigens from the surface of red blood cells was 
observed in patients with oral malignancy (89,4%), while the other 10,6% conserved the 
ABH expression. 39.4 % of the benign lesions which were diagnosed anatomophatologically 
lost the antigenic reactivity.  
 
 PRECANCEROUS 
CANCEROUS  
BENIGN LESIONS 
Parcial or total deletion 59 26 
Antigenic conservation 7 40 
Table 1. Expression of the ABH antigens in fixed tissue sections of oral lesions 
Blood-group antigens can be present on key receptors controlling cell proliferation, 
adhesion, and motility, such as epidermal growth factor receptor, integrins, cadherins, and 
CD44 (Gao et al., 2004). The expression patterns of these various receptors differ according 
to the type of normal epithelium and the type of cancer, and therefore the role of ABH 
antigens in the biology of human cancers may also vary. The function of the expression of 
ABO antigens in normal stratified oral epithelium is unclear. 
In routine diagnostic histopathology, classification of tumor type is based on the histological 
appearance of the most differentiated parts of the tumor. The prognosis of the tumor, on the 
other hand, is based partly on properties within the less differentiated parts. In most cases, 
the degree of differentiation is determined by cellular and tissue morphology and by the 
ability of the cells to synthesize certain specific products such as keratin and mucins. It has 
previously been demonstrated that the expression of cell surface carbohydrates in oral 
stratified epithelium is related to cell differentiation (Ravn & Dabelsteen, 1999). Most studies 
have dealt with alteration of carbohydrates at the cell surface.  
The results we obtained have demonstrated that the patients examined showing benign 
lesions expressed the ABH antigens in the tissues analyzed but there were significant 
differences in the experimental group (Fig.1, 2). We also found a higher intensity of oral 
disease in the group with total ABH deletion, and the occurrence of epithelial dysplasia was 
most frequently found in this group. Within the most invasive tumors sites, a deletion of 
ABH reactivity correlated significantly with the stage of tumor development and 
histological malignancy grade.  
In the sections studied, the endothelium of blood vessels was reactive with the erythrocytes 
(positive control) and adipose tissues did not react with the red blood cells (negative 
controls). 
We used the loss of the expression of ABH antigens as a marker of differentiation. 
As the expression of these antigens can be detected by monoclonal antibodies, they are a 
better objective marker of differentiation than the more commonly used subjective 
histological assessment. The presence or absence of blood group antigens has been used to 
predict the clinical course of patients with superficial transitional cell carcinoma of the 
bladder (Foresto  et al., 2000). The red-cell adherence test has been the most widely accepted 
method of antigen determination, but this technique has inherent weaknesses. Recently, the 
immunoperoxidase assay has been used to detect antigens on tumor cells. We compared 
patients using the red-cell adherence and immunoperoxidase methods on adjacent micro cut 
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sections. The red-cell adherence and immunoperoxidase methods performed similarly (89%) 
when assessing the presence or absence of antigen (Boileau  et al., 1985). 
 
Fig. 1. Cancerous lesion: non inmunoadherence of red blood cells 
 
Fig. 2. Oral benign lesion: inmunoadherence of red blood cells to the tissue 
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Oral cancer often develops clinically as a two stage process, the first step being the 
appearance of a potentially malignant lesion and the second step the development of 
carcinoma. Leukoplakia and erythroplakia are clinical changes in the oral mucosa regarded 
as potentially malignant lesions (Gao et al., 2004). It is generally accepted that tumors are 
composed of heterogeneous cell populations with different biological behaviors. To obtain 
optimal prognostic information about the tumor, therefore, the entire tumor cell population 
should be studied. Despite the somewhat non representative nature of the biopsy material, 
it was possible to show that loss of ABH antigens was associated with the spread of tumor 
(stage). This could be of diagnostic and prognostic value. 
Immunohistochemical studies of oral squamous cell carcinomas have shown loss of 
expression of A or B antigens in more than 80% of cases, all of which showed concomitant 
loss of A/B transferase (Gao et al., 2004a, 2004b). Studies of potentially malignant lesions 
have shown loss of A/B antigen in most lesions with epithelial dysplasia and in half of the 
lesions clinically. In the normal oral cavity, keratinized epithelium in the palate or gingiva 
shows little or no expression of A or B blood group antigen. Since a change from a non-
keratinized to a keratinized differentiation pattern is a characteristic of many oral 
carcinomas and potentially malignant lesions, the lack of expression of blood-group 
antigens in such lesions could be due to a change in the differentiation pattern of the 
epithelium (Ravn & Dabelsteen, 2000, Dabelsteen et al., 1975). Other study has showed that 
the sequential expression of antigen is lost in carcinomas but retained in lesions with 
epithelial dysplasia and in lesions which clinically and histologically are regarded as benign. 
It also showed that although the sequential expression of carbohydrate antigens are retained 
in lesions with epithelial dysplasia, these lesions differ from normal and benign lesions due 
to an extended distribution of one of the carbohydrate structures (Dabelsteen et al, 1988). 
Some findings have also demonstrated that malignant development in stratified oral 
epithelium is associated with aberrant glycosylation of cellular glycoconjugates and that 
there are differences between premalignant lesions and carcinomas which may prove to be 
of diagnostic significance (Dabelsteen et al, 1988). 
3. Secretor status and Lewis histo-blood group antigens 
Although the ABO blood group antigens were initially identified, by Landsteiner, as 
erythrocyte substances with a significance mainly ascribed to serology, it soon became clear 
that these antigens were found on most epithelial cells and in secretions. Today the molecular 
and genetic basis of the ABH and Lewis systems and the associated secretory phenotypes has 
been resolved (Kelly 1995). The secretor gene (FUT2) codes for an α(1,2)fucosyltransferase that 
determines the ABH secretor status and influences the Lewis phenotype of an individual. The 
secretor status is defined by the presence of H type 1 antigen in body secretions such as milk 
and saliva H type 1 antigen belongs to both the Lewis and the ABO(H) histo-blood-group 
systems and is expressed in erythrocyte membranes and in several epithelial tissues, namely 
the gastricmucosa, the upper respiratory tract and the lower genito-urinary tract (Torrado, et 
al., 2000). Although the synthesis of H type 1 antigen is dependent on the sequential action of 
several glycosyltransferases, the secretor enzyme (FUT2), an α-1,2-fucosyltransferase, is 
responsible for the transfer of fucose in an α-1,2 linkage to form the terminal H type 1 structure 
(Oriol et al., 1986) . 
The Lewis histo-blood group antigens Lewis a (Lea) and Lewis b (Leb) are carbohydrate 
structures that form epitopes on glycolipids and glycoproteins (Nishihara  et al., 1994). Two 
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independent genes determine the Lewis phenotype; the Lewis gene (Le and le), and the 
secretor gene (Se and se). Conventional Lewis blood grouping is difficult (e.g., in cancer 
patients and pregnant women) because of the presence of nongenuine Lewis negative 
individuals (Ørntoft, et al., 1991). The secretor status in Lewis-negative individuals is 
currently determined by a labor-intensive hemagglutination inhibition technique that uses 
heatinactivated saliva. In Lewis positive individuals, the secretor status is deduced from the 
Lewis phenotype: i.e.: Le(a-b+) individuals are secretors, and Le(a+b-) individuals are 
nonsecretors (Nishihara et al., 1994). The ABO blood group antigens are among the well-
known fucosylated glycans. The expression of them is regulated by several 
glycosyltransferases that add monosaccharides to a precursor molecule in a sequential 
fashion (Mandel et al., 1992). The (l,2) fucosyltransferase that forms the H antigen, an 
essential precursor of the A and B antigens, plays a regulatory role in the tissue expression 
of the ABO antigens.  
The expression and secretion of ABO antigens in epithelial cells are controlled by 
secretortype (l,2)fucosyltransferase activity, known as the Secretor (Se) transferase (FUT2 
gene product) (Narimatsu et al., 1996). Several different polymorphisms are known in the 
FUT2 gene, some called as silent mutations, while others as to non-functional enzymes. 
Homozygous individuals with non-functional enzymes are termed non-secretors (se_/_). 
About 20% of individuals are non secretors who fail to express the ABO antigen in saliva. 
On the other hand, heterozygous individuals carrying one functional allele, have secretion 
similar to the wild-type. These are termed secretors (Se) (Narimatsu et al., 1996, Koda, et al., 
1997). 
Tumor progression is often associated with altered glycosylation of the cell-surface 
proteins and lipids. The peripheral part of these cell-surface glycoconjugates often carries 
carbohydrate structures related to the ABO and Lewis blood-group antigens. We analyzed 
the FUT2 gene and Se status in patients with oral lesions (benign, pre-cancerous and 
cancerous lesions) in order to determine whether these factors could be a marker risk of 
oral cancer. In total 178 subjects were examined, half of whom suffered from oral lesions 
(benign, pre-cancerous and cancerous), while the other half were the healthy control 
group. All of them were subjected to clinical oral examinations and standard evaluation 
tests in order to establish the secretor status of their saliva (agglutination inhibition 
technique (Vengelen-Tyler,  2002). In the group of patients with oral benign, pre-
cancerous and cancerous lesions (experimental group), a pathohistological examination of 
the oral mucosa was performed. 
Patients with benign oral lesions showed hyperplasia caused by diverse agents such as 
infectious, inflammatory, traumatic, hormonal, and drugs. The premalignant lesions 
included leukoplakia and lichen planus. The malignant lesions studied were squamous cell 
carcinoma.  
Appropriate informed consent was obtained from all subjects and all procedures were 
performed according to the ethical standards established by the University of Rosario.  
Saline erythrocyte suspensions were used for serological studies. The Lewis phenotypes of 
fresh blood samples were determined by a hemagglutination method (Vengelen-Tyler, 
2002), using anti-Lea and anti-Leb monoclonal antibodies. In order to establish the secretor 
status we analyzed their saliva by the agglutination inhibition technique.  
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3.1 Inhibition test for secretor status 
Two or 3 ml of saliva were collected into wide mouthed tubes. In order to eliminate the 
mucine protein they were treated with thermal shocks. They were then centrifuged and the 
supernatants were transferred to clean test tubes and placed in a boiling water bath for 10 
minutes to inactivate salivary enzymes. To 1 drop of appropriately diluted blood grouping 
reagent (anti-A, anti-B, or Ulex europaeus lectin) we added 1 drop of the patient’s saliva. 
After incubation for 10 minutes at room temperature, we added 2 drops of 2% to 5% saline 
suspension of washed indicator red cells. Then, the tube was incubated for further 30 
minutes and centrifuged in order to macroscopically inspect for agglutination. 
Agglutination of indicator cells by antibody in tubes containing saliva indicates that the 
saliva does not contain the corresponding antigen (non-secretor status). Failure of known 
antibody to agglutinate indicator cells after incubation with saliva indicates that the saliva 
contains the corresponding antigen (secretor status). 
3.2 Molecular studies  
3.2.1 DNA isolation 
Genomic DNA was isolated from saliva samples. We designed a protocol for DNA 
extraction from these samples. They were subjected to thermal shock by successive freezing 
and thawing and centrifuged to work with the cell button. We used the technique CTAB-
DTAB (dodecyltrimethylammoniumbromide/ cetyltrimethylammoniumbromide) adding 
CTAB directly without the addition of TE buffer (Yamamoto  et al., 1990, Henry et al., 1995). 
The DNA concentration was measured spectrophotometrically at 260 nm and diluted in 
sterile water to a concentration of 100 ng per L.  
3.2.2 G428A polymorphism  
The DNA samples were analyzed by ASO-PCR (allele specific oligonucleotid – polymerase 
chain reaction) with specific primers (Operon Lab) for G428 allele and the wild type allele of 
FUT2 gene (Table 2). A fragment of 132 bp was amplified as described by Henry et al. 
(Henry et al., 1995), except for the annealing temperature modifications. According to 
gradient of PCR the Tm of the primers chosen was 66ºC. The PCR products (132 bp) were 
analyzed in 2 % agarose gel containing ethidium bromide. The categorical data were 
examined with a 2 test, and the ORs were calculated as measure of association.  
 
Primers Tm Sequence Specificity 
FUT2-Se-428-s 68,8 ºC 5’-CCGGTACCCCTGCTCGTG-3’ Se (direct) 
FUT2-se-428-f 66,6 ºC 5’-ACCGGTACCCCTGCTCGTA-3’ se (direct) 
FUT2-all-523-as 66,7 ºC 5’-CCGGCTCCCGTTCACCTG-3’ 
Non specífic 
(reverse) 
Table 2. Sequence of primers for the analysis of the G428A mutation 
In our population the nonsense mutation (428 G-A) in the FUT2 gene is the most frequent 
polymorphism. We studied the possible association between the 428 G-A in the FUT2 gene 
and oral disease progression. The genotyping revealed that 18 (20.5%) of the 89 blood 
donors were found to be non-secretors (se_/_) and 79.5 % of the healthy individuals studied 
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presented the Se gene (FUT 2) that governs the secretion of water-soluble ABH antigens into 
saliva (control group). These secreted antigens can be demonstrated in saliva by 
agglutination inhibition tests with ABH antisera and molecular biology through analysis of 
the FUT 2 gene. In contrast, twenty-eight patients (58%) with oral pre-cancerous and 
cancerous lesions were non secretors, OR = 2.43; CI 95% (1.03; 5.71) (p= 0.0407) (Table 3). We 
found a higher intensity of oral disease in the non-secretor group, and epithelial dysplasia 
was found exclusively in this group.  
 
 
Benign 
Lesions (mucoceles, 
papilloma, etc) 
Pre-cancerous + 
Cancerous 
FUT2 –Se 
(Secretor Status) 
26 20 
FUT2 –se 
(Non Secretor Status) 
15 28 
Table 3. Secretor status in patients with oral lesions 
The molecular analysis showed that 48.31% of patients was homozygous for the G428A 
mutation (the mutation present in the 2 alleles), while the other patients were homozygous 
for the secretor status (none of them presented the allele G428A), or heterozygous secretor (1 
allele presented with the mutation G428A) (Fig. 3). 
 
 
Fig. 3. The agarose gel shows the PCR products of 132 bp for the M1-M6 samples. Each 
sample was analysed for the wild type allele (Se) and for G428A allele (se) and was run 
together with secretor control (CS) and non-secretor control (CNS). 
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The secretor status is defined by the presence of H type 1 antigen in body secretions such as 
milk and saliva. H type 1 antigen belongs to both the Lewis and the ABO (H) histo-blood-
group systems and it is expressed in erythrocyte membranes and in several epithelial 
tissues. The secretor enzyme (FUT2), an α-1,2-fucosyltransferase, is responsible for the 
fucose transfer in an α-1,2 linkage to form the terminal H type 1 structure. The cell-surface 
fucosylated oligosacharides participate in several biological processes, such as 
embryogenesis, tissue differentiation, tumour metastasis, inflammation and bacterial 
adhesion (Dabelsteen, 2004). About 20% of the Caucasian population is non-secretor. Several 
disease correlations have been linked to non-secretor status. In general, being non-secretor 
results in several disadvantages regarding metabolism and immune function (Campi et al., 
2007, Le Pendu et al., 2001, Daniels, 2007).  
Our results have demonstrated that most of the individuals examined in the healthy group 
were secretor (have the FUT2 gene) (79.5 %) and there were significant difference between 
secretors and non-secretors in the experimental group. We have also found a higher 
intensity of oral disease in the non-secretor group, and the occurrence of epithelial dysplasia 
was mostly found in the non-secretor group. This study evaluated the association between 
oral lesions and polymorphisms of the Se genes. We found that oral pre-cancerous and 
cancerous lesions were increased among individuals with non secretor status and nonsense 
mutation 428G→A (Trp143→stop) (58.33%). We found 20 patients diagnosed 
histopathologically as malignant lesions despite the secretory status. We also observed that 
the red cell Lewis antigen reactivity does appear to be associated with the secretor status in 
the saliva, a conclusion supported by the observation that some individuals with Le(a-b+) 
red cells show reactivity of ABH antigens in their secretions and they have the FUT2 gene. 
The studies of patients with premalignant and malignant oral lesions, in which non-secretor 
status predominates, appear to be an associated risk marker for the development of oral 
cancer. Leukoplakia and erythroplakia are clinical changes in the oral mucosa regarded as 
potentially malignant lesions (Clausen et al., 1994, Hakomori, 1999). Certain 
histopathological changes may indicate a malignant potential in a lesion. However, the 
presence of such changes is not a reliable predictor of malignant transformation, and their 
absence does not mean that the patient is out of risk of developing a tumour (Gao et al., 
2004b). 
Although the relationship between epithelial dysplasia in a leukoplakia and malignant 
transformation of the lesion is debatable, many workers consider that the finding of 
epithelial dysplasia indicates a higher likelihood to develop malignancy. It is, however, 
more probable that the antigen changes found in the dysplastic lesions are associated with 
other factors, such as cell movement and growth rate, rather than malignancy per se 
(Dabelsteen, et al.,  1975).  
Our study evaluated the association between oral lesions and polymorphisms of the Se 
genes and secretor status. We found that oral pre-cancerous and cancerous were increased 
among individuals with non-secretor status and nonsense mutation 428G→A 
(Trp143→stop). We also demonstrated that the Le (a+b-) antigen expression was present in 
the population showing greater risk. The studies of patients with pre malignant and 
malignant oral lesions, in which non-secretor status predominates, show that this status 
appears to be an associated risk marker for the development for oral cancer. 
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4. CD44 
CD44 is a transmembrane glycoprotein that binds hyaluronan, extracellular matrix proteins 
and growth factors. Alternative splicing of a single gene generates a family of splice variants 
(CD44vl-10) in addition to the standard isoform.  Cell adhesion molecules are essential for 
maintaining the stable structure of stratified squamous epithelium. In normal epithelium, 
keratinocytes are attached to each other and to the underlying basement membrane. Cell 
adhesion, however, must be dynamic to facilitate the mobility and turnover of cells. In 
dynamic situations, keratinocytes alter their cell-cell and cell-ECM interactions by virtue of 
altered expression and function of cell adhesion molecules. The expression of cell adhesion 
molecules is normally tightly regulated-forming, persisting, or declining in an ordered 
fashion. This allows for controlled cell proliferation, mobility, differentiation, and survival. 
Many of these processes are misregulated in malignant tumours, and it has been shown that 
many of the characteristics of tumour cells are attributable to the aberrant expression or 
function of cell adhesion molecules. However, multiple CD44 isoforms are expressed by 
normal stratified squamous epithelia, such as the epidermis and the lining of the oral cavity 
(Hudson et al., 1996).  
The neoplastic transformation of normal epithelial cells to metastatic tumour cells is a 
complex process involving a number of alterations in the expression of genes implicated in 
cell proliferation, cell adhesion and cell migration. Tumour progression is the process by 
which tumour cells acquire malignant properties, such as progressive growth, invasion and 
metastasis (Nowell, 1986). One of the genes involved in these processes is CD44 which 
appears to be one of the most promising candidates as a cancer diagnosis marker (Otavia, et 
al., 2001).  Several studies have provided evidence that the expression of CD44 is specifically 
altered in many types of tumours. They show aberrant expression and processing of CD44 
transcripts and cell surface expression of CD44 appears to change profoundly during 
tumour metastasis, particularly during the progression of various carcinomas 
(Assimakopoulos et al., 2002). Numerous studies based on immunohistochemical analyses 
of paraffin-embedded or frozen tissue sections using different monoclonal antibodies to 
CD44 isoforms and molecular biological techniques have provided evidence that in many 
types of tumours there is overexpression of CD44 isoforms. 
We investigate by confocal microscopy, the expression of CD44 protein in epithelial cells 
obtained from saliva samples from patients with oral lesions. We studied 28 patients with 
various oral lesions (benign, pre-cancerous and cancerous), and a control group (n = 32) 
who had no alterations. We worked with saliva samples subjected to thermal shock and 
washed with phosphate buffered saline. They were concentrated by centrifugation. Then 106 
cells were incubated with anti-CD44 antibody suitable dilution for 30 min at room 
temperature. After washing with phosphate buffered saline, it was incubated with 
secondary antibody labeled with allophycocyanin (APC). Parallel internal controls were 
processed for each sample. The different cell suspensions were washed with phosphate 
buffered saline and observed by confocal microscopy (Nikon C1) using 639 nm red laser. 
The results obtained showed fluorescence corresponding to the presence of CD44 protein in 
samples from patients diagnosed with cancer and precancer. A higher intensity was 
observed in individuals with a pathological diagnosis of squamous cell carcinoma (Fig 4). In 
contrast, samples from patients with benign lesions showed no fluorescence images as 
samples of the control group (Fig. 5). These findings indicate that overexpression of CD44 
molecule analyzed could be considered as a marker of risk in individuals with oral lesions. 
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Fig. 4. Image of squamous carcinoma cells obtained by confocal microscopy. The over 
expression of CD44 protein is noted by the red fluorescence observed on cell membranes 
and in cytoplasms. 
 
 
Fig. 5. Image of benign lesions cells obtained by confocal microscopy. No red fluorescence is 
observed indicating the absence of CD44 protein expression. 
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Studies on early premalignant lesions and on early stage malignancies of several types of 
common tumours, such as breast, bladder and colon, have reported increased CD44 isoform 
expression and aberrant CD44 transcript processing, but also a marked heterogeneity in the 
pattern of expression within the tumour. These specific alterations in CD44 expression 
become clear and distinct with tumour progression, with higher expression levels achieved 
in invasive and metastatic tumour cells. Several mechanisms, based on the properties of 
CD44 as the major hyaluronan CD44 in squamous cell carcinomas receptor and as a signal 
transmitter and growth presenting molecule, have been proposed to explain the role of 
elevated CD44 expression during tumour development and progression (Knudson, 1998). 
5. Conclusion 
Clinical examination and histopathological studies of biopsied material are the classical and 
the most accepted diagnostic methods used for precancerous and cancerous oral lesions. 
While conventional oral examination may be useful in the discovery of some oral lesions, it 
does not identify all potentially premalignant and/or malignant lesions. 
It has been shown that leukoplakias from patients who subsequently developed malignancy 
all demonstrated loss of expression of histo-blood group antigen in the lesions that preceded 
the carcinomas. This may indicate that the change in expression of A/B antigen is an early 
event in the malignant development process.  
We propose that areas of SRCA-test negative epithelium are closely related to invasive 
carcinomas and may be their precursor lesions. However, as it is generally accepted that 
cancer cells must undergo a whole series of changes to become metastatic, it is remarkable 
the degree of expression of a single carbohydrate structure was significantly correlated with 
aggressive clinical behaviour of the tumour. It is therefore possible that further prognostic 
information can be obtained by detecting a group of other related carbohydrate structures at 
the cancer cell membranes. 
Our findings also demonstrate that the Se genotypes affect the risk of developing malignant 
oral disease defined by the secretor status. The study also evaluated the association between 
oral lesions and polymorphisms of the Se genes. We found that oral pre-cancerous and 
cancerous lesions were increased among individuals with non secretor status and nonsense 
mutation 428G→A (Trp143→stop). 
Thus, we think that CD44 might be a good candidate as a predictor of prognosis in this 
group of cancers. However, a larger series with clinical follow-up and study of other 
biological markers of tumor progression is needed to determine whether it is an 
independent prognostic factor or not. 
In summary, our results indicate that at the same time as the morphological changes that 
occur during the process of oral carcinogenesis, another series of events occurs. Further 
follow-up studies are required to clarify the role of predictive markers of risk in precursor 
lesions of oral cancer 
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